Johnson & Johnson invites you to join us on July 6 for an exclusive scientific symposium spotlighting groundbreaking advancements in lung cancer and our collaborative work with some of the brightest minds in the oncology ecosystem. This curated evening is designed to bring together leaders across research, innovation, and investment for meaningful dialogue and connection.
What to Expect
-Keynote Presentation
-Insights into the latest scientific and clinical advancements in lung cancer
-Expert Panel Discussion
-Featuring Johnson & Johnson oncology leaders alongside invited industry guests
-Interactive Q&A
-Engage directly with speakers and fellow attendees
-Networking Reception
Connect with peers, innovators, and decision makers shaping the future of oncology. Don’t miss this opportunity to be part of an intimate, high impact discussion at the forefront of lung
cancer innovation.
This event is not open to service providers or vendors. If you’re interested in future partnership opportunities, please feel free to contact us separately - Merritt Carver mcarver3@its.jnj.com.
Dr. Bauml is the Lung/H&N Cancer Disease Area Stronghold Leader at Johnson & Johnson Innovative Medicine. As the Lung/H&N Cancer DAS leader, Dr. Bauml is responsible forend-to-end Lung/H&N Cancer Development including mature assets (Rybrevant and Lazertinib) as well as identifying new assets in early development and/or partnerships.
He received his undergraduate from Tufts University, Boston and completed his residency and earned his MD at the Icahn School of Medicine at Mt. Sinai. He completed his fellowship at the University of Pennsylvania. After his fellowship, Dr. Bauml was a faculty member at the University of Pennsylvania for 8 years, treating patients with lung and H&N cancers.
Alice Ly serves as a Vice President on Alexandria’s Life Science team, where she oversees Alexandria Venture Investments’ portfolio, supports the tenant portfolio, convenes ecosystem-building initiatives and community events across the Pacific Northwest, and leads Alexandria LaunchLabs – Seattle, partnering with entrepreneurs to support early-stage company creation. Previously, Alice led the Life Science vertical at the Harvard Innovation Labs. She holds a Ph.D. in Neurobiology from Yale University.
Dr. Allison Rhines is a Senior Director of Oncology External Innovation, where her focus is on the evaluation of external assets for partnership and investment. Dr. Rhines has served in multiple innovation-focused roles at J&J, including most recently as Head of the Houston JLABS, where she had portfolio responsibility for attracting and retaining scientific-aligned companies in JLABS, as well as supporting the broader ecosystem through external presence and partnerships. Prior to this, she served as an Early Innovation Partner at the Johnson & Johnson West North America Innovation Center in San Francisco.
Â
Prior to re-joining J&J, Allison served as a Program Officer in the Bill & Melinda Gates Foundation’s early innovation group, now known as the Gates Biotech Accelerator. There, she led the Foundation’s COVID-19 Transmission Biology portfolio, the portfolio of investments focused on the basic transmission biology of the SARS-CoV-2 virus, for two years during the COVID-19 pandemic. Allison previously held a range of operating and investing roles in the venture-backed startup space, with focus areas including oncology, infectious disease, and AI-assisted therapeutics discovery platforms.
Â
Dr. Rhines completed her postdoctoral fellowship at J&J. She holds an PhD in Biology and BA from Stanford, an MBA from INSEAD in Singapore and an MPhil from the University of Cambridge in the UK.
Dozie leads Oncology External Innovation activities for Johnson & Johnson in West North America, driving strategic partnerships, technical due diligences, and championing equity investments to advance the Oncology portfolio. He has spearheaded collaborations and numerous evaluations, shaping transformational research and development initiatives.
Previously, Dozie headed Johnson & Johnson Innovation JLABS in Canada, supporting over 100 life science start-ups at one of the country’s largest life science incubators. His leadership spans internal and external ecosystems, complemented by advisory roles with the University of Michigan’s MTRAC program and Creative Destruction Labs.
He serves on the boards of the Society of Toxicology and other not for profit life science organizations and has advised government bodies in Canada and Nigeria on Science and Innovation. As a scientist, Dozie has also contributed to the development of multiple Oncology products, including Tecvayli, Talvey, Rybrevant and others.
He has authored 10 book chapters, 24 peer-reviewed articles and numerous meeting abstracts. Dozie holds a dual Ph.D. in Comparative Medicine and Integrative Toxicological Sciences from Michigan State University, where he also completed a Veterinary Pathology residency. He earned his D.V.M. from the University of Nigeria and is board-certified in both Toxicology and Veterinary Pathology.
Aaron Foster, Ph.D. is the Chief Scientific Officer at Outpace Bio, a Seattle-based clinical-stage biotechnology company solving durable efficacy, safety, and scalability for cancer cell therapy. He has over three decades of drug development expertise and a record of leading research teams to advance engineered cell therapies from their initial discovery phase into clinical trials. At Outpace, Dr. Foster spearheaded the development of the organization's ex vivo cell therapy pipeline: incorporating cutting-edge protein design and gene engineering technologies that significantly improve the cells' expansion, persistence and overall therapeutic efficacy. In addition, Dr. Foster is advancing the OUTDRIVE™ in vivo CAR-T platform. Prior to joining Outpace, Dr. Foster held research leadership roles at Sana Biotechnology and Bellicum Pharmaceuticals. He was also a faculty member at Baylor College of Medicine, within the Center for Cell and Gene Therapy.
This program is from Johnson & Johnson and represents a selection of activities from across our Innovation Centers, JLABS and JJDC. The information in this program is for informational purposes only. The information is either proprietary or licensed to Johnson & Johnson and its affiliates or is provided by or proprietary to third parties. In case of third-party information, please note that only those third parties that provided or own this information are responsible for it. By providing this information, Johnson & Johnson do not endorse these third parties or any of the information provided in this program. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of Johnson & Johnson. Johnson & Johnson is not responsible or liable for any actions you do or do not take in relation to this information and are not responsible for any use of this information by you. By providing the information in this program, Johnson & Johnson does not make any representations, warranties, or assurances, express or implied, as to the content or the information presented in this program and is not responsible for any use by or alterations of this information by you. Johnson & Johnson hereby expressly disclaims any and all guarantees, representations, warranties, or assurances and assumes no responsibility or liability, direct or indirect in relation to the information in this program.
